Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, Gasbarrini G: L-carnitine improves glucose disposal in type 2 diabetic patients
Conflict of interests Professor Hanefeld has received speaking honoraria from Bayer Healthcare AG
Patients using or considering compounded semaglutide or tirzepatide should not substitute allulose as a replacement, as the clinical efficacy and magnitude of effect are fundamentally different
Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH)
Headaches: Some users report headaches, which may be due to changes in blood sugar levels or GH fluctuations
A: Clinical trials have shown that semaglutide (Wegovy) produces an average weight loss of approximately 15% of body weight over approximately 68 weeks, while tirzepatide (Zepbound) has demonstrated average weight reductions of up to 22%